Numerical Statements of the Holy Quran Based on Verses, Words, and Letters in Makki and Madani Sura
International Journal of Cultural and Religious Studies · 2022
DOI: 10.32996/ijcrs.2022.2.2.3 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cultural and Religious Studies, 2022. Verfasst von Md. Rashidul Hasan und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Thy Quran is such a Holy book that has several purposes and objectives for different people. The main objective of this study is to provide numerical statements of the Holy Quran based on verses, words, and letters in Makki and Madani sura. The study intended to compute several descriptive statistics, construct frequency distribution and present it graphically. The data used in this study were extracted from Quran Code software. The result of the study found that the average number of verses, words, and letters in Madani sura is higher than the Makki sura though the number of Makki sura is higher than the Madani sura. The number of verses, words, and letters per Makki and Madani sura is exponentially declining. The first Arabic letter A-lif(ا) occurs at maximum times, and another Arabic letter Dh-aa(ظ) occurs at minimum times than all other letters in both Makki and Madani sura.
Zitieren
APA
Hasan, M. R., & Mamun, F. E. (2022). Numerical Statements of the Holy Quran Based on Verses, Words, and Letters in Makki and Madani Sura. International Journal of Cultural and Religious Studies. https://doi.org/10.32996/ijcrs.2022.2.2.3
Vancouver
Hasan MR, Mamun FE. Numerical Statements of the Holy Quran Based on Verses, Words, and Letters in Makki and Madani Sura. International Journal of Cultural and Religious Studies. 2022. doi:10.32996/ijcrs.2022.2.2.3
BibTeX
@article{Hasan2022,
author = {Hasan, Md. Rashidul and Mamun, Fazly Ealahi},
title = {Numerical Statements of the Holy Quran Based on Verses, Words, and Letters in Makki and Madani Sura},
journal = {International Journal of Cultural and Religious Studies},
year = {2022},
doi = {10.32996/ijcrs.2022.2.2.3}
}
EUVIMED